Inogen to Participate in Upcoming Investor Conferences

GOLETA, Calif.--(BUSINESS WIRE)-- Inogen, Inc. (NASDAQ: INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, announced today that it will be participating in two upcoming investor conferences.

Inogen’s President and COO, Scott Wilkinson and CFO, Alison Bauerlein, are scheduled to present at the J.P. Morgan 35th Annual Healthcare Conference in San Francisco on Tuesday, January 10, 2017 at 4:00pm PT.

Mr. Wilkinson is also scheduled to present at the 19th Annual Needham & Company Growth Conference in New York City on Thursday, January 12, 2017 at 10:00am ET.

Interested parties can access the live audio webcast for both of these conference presentations from the Events section of the Investor Relations page on the Inogen website at www.inogen.com. Both webcast replays will be available approximately one hour after the conclusion of the live presentations and will remain available for approximately 90 days.

Inogen has used, and intends to continue to use, its Investor Relations website, http://investor.inogen.com/, as a means of disclosing material non-public information and for complying with its disclosure obligations under Regulation FD. For more information, visit http://investor.inogen.com/.

About Inogen

Inogen is innovation in oxygen therapy. We are a medical technology company that develops, manufactures and markets innovative oxygen concentrators used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions.

For more information, please visit www.inogen.com.

View source version on businesswire.com: http://www.businesswire.com/news/home/20161221005829/en/

Inogen, Inc.
Investor Relations Contact:
[email protected]
805-562-0500 ext. 7
or
Media Contact:
Byron Myers
805-562-0503

Source: Inogen, Inc.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Taylor Morrison Names Jeremy Hampson Division President of Jacksonville
• Restart Life Sciences Leverages University of Manitoba RCFTR Collaboration for Pre-Production Transition of New Protein Frameworks
• Spero Therapeutics Announces $105 Million Non-Recourse Non-Dilutive Financing Backed by a Portion of Utebzi Milestones & Royalties